Press release
The Staphylococcus Aureus Bacteremia Market Size in the 7MM is projected to grow with a significant CAGR by 2034, estimates DelveInsight
Staphylococcus aureus Bacteremia Market
To Know in detail about the Staphylococcus aureus Bacteremia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here @ https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Some of the key facts of the Staphylococcus aureus Bacteremia Market Report:
• During the analysis of Staphylococcus aureus Bacteremia, it was observed that Staphylococcus aureus Bacteremia is among the most dominant causes of nosocomial bacteremia, hospital-acquired pneumonia, and surgical site infections.
• It was observed that the estimated incidence rate of Staphylococcus aureus Bacteremia ranges from 20 to 50 cases per 100,000 population per year.
• It was noted that Staphylococcus aureus Bacteremia was the predominant cause of nosocomial bacteremia in North America, accounting for 26.0% of cases, and was the second most common cause of infections in Europe, with an incidence of 19.5%, a few years ago.
• During the analysis, it was found that Spain reported an incidence of 14 cases of Staphylococcus aureus Bacteremia per 100,000 inhabitants a few years ago.
• It was observed that among adult patients with Staphylococcus aureus Bacteremia, 58.7% were classified as healthcare-associated (HCA-SAB).
• The epidemiology of Staphylococcus aureus Bacteremia is expected to change during the forecast period (2024-2034).
• The leading Staphylococcus aureus Bacteremia Companies such as Basilea Pharmaceutical, Armata Pharmaceuticals, Inc., Destiny Pharmaceuticals, and others
• Promising Staphylococcus aureus Bacteremia Therapies: Ceftobiprole, AP-SA02, XF-73, and others
Key benefits of the Staphylococcus aureus Bacteremia Market report:
1. Staphylococcus aureus Bacteremia market report covers a descriptive overview and comprehensive insight of the Staphylococcus aureus Bacteremia Epidemiology and Staphylococcus aureus Bacteremia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Staphylococcus aureus Bacteremia market report provides insights on the current and emerging therapies.
3. Staphylococcus aureus Bacteremia market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Staphylococcus aureus Bacteremia market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Staphylococcus aureus Bacteremia market.
Download the report to understand which factors are driving Staphylococcus aureus Bacteremia epidemiology trends @ https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Staphylococcus aureus Bacteremia Market
The dynamics of the Staphylococcus aureus Bacteremia market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.
Staphylococcus aureus Bacteremia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Staphylococcus aureus Bacteremia Epidemiology Segmentation
• Total Incident Cases of Staphylococcus aureus Bacteremia
• Type-specific Cases of Staphylococcus aureus Bacteremia
• Antibiotic-Resistant Cases of Staphylococcus aureus Bacteremia
• Gender-specific Cases of Staphylococcus aureus Bacteremia
• Age-specific Cases of Staphylococcus aureus Bacteremia
• Treatable Cases of Staphylococcus aureus Bacteremia
Staphylococcus aureus Bacteremia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Staphylococcus aureus Bacteremia market or expected to get launched during the study period. The analysis covers Staphylococcus aureus Bacteremia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Staphylococcus aureus Bacteremia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Staphylococcus aureus Bacteremia Marketed Drugs
• ZEVTERA: Basilea Pharmaceutica
Ceftobiprole, the active moiety of the prodrug ceftobiprole medocaril, is an advanced-generation cephalosporin antibiotic for intravenous administration. It exhibits rapid bactericidal activity against a wide range of Gram-positive bacteria, including Staphylococcus aureus, including methicillin-resistant strains (MRSA), and Gram-negative bacteria. ZEVTERA is indicated for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB). Basilea has entered into license and distribution agreements covering more than 80 countries.
Emerging Staphylococcus aureus Bacteremia Drugs
The Staphylococcus aureus Bacteremia market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including Armata Pharmaceuticals, and others, have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.
• AP-SA02: Armata Pharmaceuticals
AP-SA02, developed by Armata Pharmaceuticals, is a novel biologic product candidate comprising natural lytic phages that target the problematic pathogen, Staphylococcus aureus, and offers robust therapeutic attributes. Armata has received FDA clearance for its Investigational New Drug (IND) application to initiate the "diSArm" study - a Phase Ib/IIa, randomized, double‐blind, placebo‐controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP‐SA02 as an adjunct to best available antibiotic therapy compared to best available antibiotic therapy alone for the treatment of adults with bacteremia due to Staphylococcus aureus.
Discover more about therapies set to grab major Staphylococcus aureus Bacteremia market share @ https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Staphylococcus aureus Bacteremia Therapies and Key Companies
• Ceftobiprole: Basilea Pharmaceutical
• AP-SA02: Armata Pharmaceuticals, Inc.
• XF-73: Destiny Pharmaceuticals
Scope of the Staphylococcus aureus Bacteremia Market Report
• Study Period: 2020-2034
• Coverage: 7MM
• Key Staphylococcus aureus Bacteremia Companies: Basilea Pharmaceutical, Armata Pharmaceuticals, Inc., Destiny Pharmaceuticals, and others
• Key Staphylococcus aureus Bacteremia Therapies: Ceftobiprole, AP-SA02, XF-73, and others
• Staphylococcus aureus Bacteremia Therapeutic Assessment: Staphylococcus aureus Bacteremia current marketed and Staphylococcus aureus Bacteremia emerging therapies
• Staphylococcus aureus Bacteremia Market Dynamics: Staphylococcus aureus Bacteremia market drivers and Staphylococcus aureus Bacteremia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Staphylococcus aureus Bacteremia Unmet Needs, KOL's views, Analyst's views, Staphylococcus aureus Bacteremia Market Access and Reimbursement
Get a Free sample for the Staphylococcus aureus Bacteremia Market Report @ https://www.delveinsight.com/sample-request/staphylococcus-aureus-bacteremia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Contents
1. Staphylococcus aureus Bacteremia Market Report Introduction
2. Executive Summary for Staphylococcus aureus Bacteremia
3. SWOT analysis of Staphylococcus aureus Bacteremia
4. Staphylococcus aureus Bacteremia Patient Share (%) Overview at a Glance
5. Staphylococcus aureus Bacteremia Market Overview at a Glance
6. Staphylococcus aureus Bacteremia Disease Background and Overview
7. Staphylococcus aureus Bacteremia Epidemiology and Patient Population
8. Country-Specific Patient Population of Staphylococcus aureus Bacteremia
9. Staphylococcus aureus Bacteremia Current Treatment and Medical Practices
10. Staphylococcus aureus Bacteremia Unmet Needs
11. Staphylococcus aureus Bacteremia Emerging Therapies
12. Staphylococcus aureus Bacteremia Market Outlook
13. Country-Wise Staphylococcus aureus Bacteremia Market Analysis (2019-2032)
14. Staphylococcus aureus Bacteremia Market Access and Reimbursement of Therapies
15. Staphylococcus aureus Bacteremia Market Drivers
16. Staphylococcus aureus Bacteremia Market Barriers
17. Staphylococcus aureus Bacteremia Appendix
18. Staphylococcus aureus Bacteremia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About Us
DelveInsight is a leading focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and pharma sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The Staphylococcus Aureus Bacteremia Market Size in the 7MM is projected to grow with a significant CAGR by 2034, estimates DelveInsight here
News-ID: 4413896 • Views: …
More Releases from DelveInsight Business Research LLP
Optic Neuritis Therapeutics Market Size in the 7MM was ~USD 3 Million in 2024 an …
DelveInsight's "Optic Neuritis Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Optic Neuritis, historical and forecasted epidemiology as well as the Optic Neuritis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock detailed insights into the Optic Neuritis Market by downloading the comprehensive report from DelveInsight @ https://www.delveinsight.com/sample-request/optic-neuritis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Optic Neuritis…
Stargardt Disease Therapeutics Market Size in the 7MM is anticipated to increase …
DelveInsight's "Stargardt Disease Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stargardt Disease, historical and forecasted epidemiology as well as the Stargardt Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Discover Key Insights into the Stargardt Disease Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/stargardt-disease-stgd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Stargardt Disease Market Report
• In August 2026, Belite…
Surgical Site Infections Therapeutics Market Size in the 7MM is anticipated to i …
DelveInsight's "Surgical Site Infections Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Surgical Site Infections, historical and forecasted epidemiology as well as the Surgical Site Infections market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
Discover Key Insights into the Surgical Site Infections Market with DelveInsight's In-Depth Report @ https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Surgical Site Infections Market Report
• In…
Nontuberculous Mycobacteria Infections Treatment Market Size was more than USD 7 …
DelveInsight's "Nontuberculous Mycobacterial Infections Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of NTM Infections, historical and forecasted epidemiology, as well as the NTM Infections market trends in the United States.
Explore the intricate details of the Nontuberculous Mycobacterial Infections Market @ https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-ntm-infections-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash
Key Takeaways from the Non-Tuberculous Mycobacterial Infections Market Report
• In August 2026, MicuRx Pharmaceuticals received FDA clearance for the IND application for MRX-5, enabling the company…
More Releases for Staphylococcus
Rise In Prevalence Of Methicillin-Resistant Staphylococcus Aureus Infections: Po …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Methicillin-Resistant Staphylococcus Aureus (MRSA) Drugs Market Through 2025?
In recent times, the market size of drugs for methicillin-resistant staphylococcus aureus (MRSA) has seen continuous growth. The market, which was worth $2.35 billion in 2024, is projected to expand to $2.47 billion in…
Leading Growth Driver in the Methicillin-Resistant Staphylococcus Aureus (MRSA) …
What market dynamics are playing a key role in accelerating the growth of the methicillin-resistant staphylococcus aureus (mrsa) drugs market?
The growth of the methicillin-resistant Staphylococcus aureus drugs market is expected to be fuelled by the rise in Hospital Acquired Infections (HAIs). Patients acquire these infections while being treated at a healthcare center, usually 48 hours or more post admissions. The root causes behind HAIs include contaminated medical apparatus, lax hand…
Methicillin-Resistant Staphylococcus Aureus Testing Market Size, Share, Developm …
LP INFORMATION offers a latest published report on Methicillin-Resistant Staphylococcus Aureus Testing Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report.
According to this study, over the next five years the Methicillin-Resistant Staphylococcus Aureus Testing market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million…
Staphylococcus Aureus Testing Market In-Depth Market Research Report 2027
A wide range of human clinical infection caused by Staphylococcus Aureus such as Skin, soft tissue, bacteremia, infective endocarditis and others are the major infection caused by Staphylococcus Aureus. The increased use of Staphylococcus Aureus testing in the diagnosis of staph infection grow rapidly, due to the availability of the various advanced test to screen the pathogen efficiently. There is a number of tests present in the market for Staphylococcus…
Methicillin-resistant Staphylococcus Aureus Therapeutics Pipeline Analysis 2018
MRSA infection caused by specific "staph" bacteria that is often resistant to most of antibiotic treatments. S. aureus (SA) is listed as a ‘superbug’ by U.S. Centers for Disease Control and Prevention (CDC). MRSA can either be present harmlessly on the skin (colonization) or enter the body (e.g. through broken skin) and cause an infection. The study analyzed that MRSA infection therapeutics pipeline comprises approximately 52 drug candidates in different…
Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market – Driver
Methicillin-Resistant Staphylococcus Aureus (MRSA) is a type of staphylococcus aureus, which became resistant to methicillin, amoxicillin, penicillin, oxacillin, and other such commonly used antibiotics. Staphylococcus aureus harbors on the skin and nasal passage of about one third of the world population, which comprises around 33%, as per Centers for Disease Control and Prevention (CDC) review 2015. MRSA can be classified into two types, based on mode of infection – Hospital…
